# AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

- Link: https://www.directorstalkinterviews.com/astrazeneca-and-daiichi-sankyo-secure-fda-approval-for-enhertu-in-early-breast-cancer/4121251724
- Published: 2026-05-18T07:29:51+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo’s _Enhertu_ (trastuzumab deruxtecan) has been approved by the
US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment
of patients with HER2-positive early breast cancer based on results from the DESTINY-
Breast11 and DESTINY-Breast05 Phase III trials, respectively.

In the neoadjuvant setting, _Enhertu_ followed by a taxane, trastuzumab, and pertuzumab(
THP) has been approved for the treatment of adult patients with HER2-positive Stage
II or Stage III breast cancer. In the adjuvant setting, _Enhertu_ has been approved
for the treatment of adult patients with HER2-positive breast cancer who have residual
invasive disease following trastuzumab (with or without pertuzumab) and taxane-based
treatment.

> **Shanu Modi, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, 
> said**: “HER2-positive breast cancer is an aggressive disease, and our goal is
> to reduce the risk of recurrence for patients as early as possible to achieve 
> the best long-term outcomes. The neoadjuvant setting offers the earliest opportunity
> to improve outcomes, while the adjuvant setting provides another important chance
> to prevent recurrence for patients with residual disease after surgery. These 
> two new indications in HER2-positive early breast cancer will evolve how we treat
> patients in these settings and support trastuzumab deruxtecan as a potential new
> standard of care in early-stage disease.”

> **Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit,
> AstraZeneca, said**: “HER2-positive early disease is considered highly curable,
> however up to one in four patients still experience disease recurrence, underscoring
> the need for new options in this setting. These approvals mark an important step
> forward, expanding the possibility of cure to more patients for the first time
> in many years and positioning _Enhertu_ as a foundational treatment in early breast
> cancer.”

> **Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi
> Sankyo, Inc. said**: “_Enhertu_ has redefined the treatment of HER2-expressing
> breast cancer with practice-changing data across six breast cancer indications
> in seven years. _Enhertu_ is now approved in the US across both early and metastatic
> HER2-positive breast cancer, accomplishing what we set out to achieve a little
> over a decade ago for patients at the start of our comprehensive clinical development
> programme.”

> **Victoria Smart, Senior Vice President, Mission, Susan G. Komen, said**: “Providing
> patients with early breast cancer more options to help prevent progression to 
> metastatic disease can lead to improved outcomes. Progression and recurrence remain
> among the most significant unmet needs for those diagnosed with early breast cancer,
> and continued advances in treatment bring new hope to patients and families facing
> this disease.”

In DESTINY-Breast11, _Enhertu_ followed by THP as a neoadjuvant treatment demonstrated
a pathologic complete response (pCR) rate of 67.3% compared with 56.3% for dose-
dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP], an improvement
of 11.2% (95% confidence interval [CI] 3.9-18.3; p=0.003). At the time of the pCR
analysis, 29 patients (4.5%) had event-free survival (EFS) events, and 12 patients(
1.9%) had overall survival (OS) events. The results were published in Annals of 
Oncology.^(1)

In DESTINY-Breast05, _Enhertu_ as an adjuvant treatment reduced the risk of invasive
disease recurrence or death (invasive disease-free survival [IDFS]) by 53% compared
to trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with
residual invasive disease following neoadjuvant therapy (hazard ratio [HR] 0.47;
95% CI 0.34-0.66; p<0.0001). At three years, 92.4% of patients in the_ Enhertu_ 
arm were alive and free of invasive disease, compared with 83.7% of those in the
T-DM1 arm, with 51 (6%) events in the _Enhertu_ arm and 102 (12%) in the T-DM1 arm.
The results were published in The New England Journal of Medicine.^(2)

Data from both trials were presented at the 2025 European Society for Medical Oncology(
ESMO) Congress.

Based on the DESTINY-Breast05 results, trastuzumab deruxtecan (_Enhertu)_ has been
included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^(
®)) as a Category 1 recommended treatment in the adjuvant setting for patients with
HER2-positive early breast cancer with residual disease and a high risk of recurrence
following preoperative therapy. See NCCN Guidelines^(®) for detailed recommendations.

No new safety concerns were identified with _Enhertu_ in the DESTINY-Breast11 or
DESTINY-Breast05 trials.

In DESTINY-Breast11, _Enhertu_ followed by THP showed similar rates of drug-related
overall adverse events (AEs) and interstitial lung disease (ILD)/pneumonitis as 
ddAC-THP, and lower rates of Grade 3 or higher AEs, serious AEs, AEs leading to 
treatment interruptions, left ventricular dysfunction and haematological toxicities.

In DESTINY-Breast05, _Enhertu_ and T-DM1 showed similar rates of overall drug-related
AEs and Grade 3 or higher AEs. Adjudicated drug-related ILD/pneumonitis occurred
in 9.6% of patients in the _Enhertu_ arm and 1.6% of patients in the T-DM1 arm. 
The majority of ILD/pneumonitis events were low grade in both arms. There were seven
Grade 3 events and two deaths (Grade 5) in the _Enhertu_ arm.

The DESTINY-Breast11 and DESTINY-Breast05 US regulatory submissions were both reviewed
under Project Orbis, which provides a framework for concurrent submission and review
of oncology medicines among participating international partners. Separate regulatory
applications for both trials are also under review in other countries. DESTINY-Breast05
previously received Priority Review and Breakthrough Therapy Designation by the 
FDA.

_Enhertu_ is already approved in more than 95 countries, including the US, as a 
treatment for patients with HER2-positive metastatic breast cancer.

_Enhertu_ is a specifically engineered HER2-directed DXd antibody drug conjugate(
ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised
by AstraZeneca and Daiichi Sankyo.

**Financial Considerations **

Following these approvals in the US, an amount of $155 million is due from AstraZeneca
to Daiichi Sankyo as milestone payments for both these indications. Sales of _Enhertu_
in the US are recognised by Daiichi Sankyo. For further details on the financial
arrangements, please consult the collaboration agreement from March 2019.

**References**

1.   Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone
or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive
early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase
III trial. _Ann Oncol_. 2026;37(2):166-179.

2.   Loibl S, et al. Trastuzumab deruxtecan in residual HER2-positive early breast
cancer. _N Engl J Med_. 2026;394(9):845-857.

Share on:
